New Immunotherapy Approaches Show Promise for Hard-to-Treat Melanoma
New immunotherapy approaches targeting CD8+ T cells show 67% response rates in hard-to-treat melanoma patients who failed checkpoint inhibitors.
97 articles
New immunotherapy approaches targeting CD8+ T cells show 67% response rates in hard-to-treat melanoma patients who failed checkpoint inhibitors.
Researchers identified a gene expression pattern that predicts which prostate cancer patients will benefit from immunotherapy combination treatment.
A novel breast cancer combination therapy shows early promise for high-risk HER2-negative patients in the I-SPY 2.2 trial results.
Researchers discover that ATM gene mutations in pancreatic cancer reprogram surrounding tissue, offering a precision medicine pathway for 17-25% of patients...
Women ages 40 to 74 should get mammograms every two years for average breast cancer risk, but those with family history may need earlier or more frequent...
New research reveals that gut microbiome imbalances reduce immunotherapy effectiveness for skin cancer and other cancers by up to 70%, but targeted...
Colorectal cancer cases have jumped 80% in adults ages 30 to 50 since the 1990s, prompting major screening guideline changes.
Ovarian cancer kills 140,000 women yearly because it's rarely caught early. Unlike breast cancer screening, there's no reliable early detection test, making...
Researchers at OHSU found that B cells can settle permanently in tissues and neutralize cancer cells when trained with vaccines, offering a localized...
About 1.5 million prostate biopsies occur annually in the US, but experts say most are unnecessary.
Ovarian cancer kills roughly 140,000 women yearly worldwide, yet receives far less attention than breast cancer.
FDA approves pembrolizumab plus chemotherapy for platinum-resistant ovarian cancer, extending survival by 4.2 months in a landmark trial.
China's top hospitals now offer comprehensive cancer screening with advanced imaging technology at a fraction of Western costs, attracting international...
Nearly 50% of cancer deaths in the US are linked to modifiable risk factors like smoking, weight, and alcohol.
Researchers found that liver cells, not immune cells, are the real bottleneck in mRNA cancer vaccine effectiveness.
A major study finds that prostate cancer overdiagnosis jumps dramatically with age, reaching 58% by age 80.
A renowned breast surgeon becomes the inaugural holder of an endowed chair dedicated to surgical excellence, positioning her research on genetic risk factors...
Opdivo, a checkpoint inhibitor immunotherapy, blocks cancer's ability to hide from immune cells, offering new hope for melanoma and other skin cancers.
New technologies combining artificial intelligence, MRI imaging, and biomarker testing are transforming prostate cancer screening to catch aggressive tumors...
Tumor-associated macrophages sabotage cancer treatment in ovarian, cervical, and endometrial cancers by creating immunosuppressive barriers.
Researchers discovered a protein called HOXD13 that fuels melanoma growth while blocking immune attacks.
A large clinical trial found that combining three cancer drugs didn't improve survival better than two drugs alone, challenging assumptions about combination...
A first-in-class drug combination achieved a 60% response rate in ovarian cancer patients with specific genetic mutations, offering hope for those with limited...
Only 30% of melanoma patients respond to immunotherapy, but researchers are uncovering how tumors hide from the immune system.
PSA blood tests detect prostate changes, but they're just one piece of prostate cancer screening.
A major study finds HPV vaccines cut cancer risk in men by nearly 50%, protecting against head and neck, esophageal, anal, and penile cancers.
Researchers are developing a blood-based test to personalize breast cancer screening frequency, moving away from one-size-fits-all mammogram schedules.
The orphan oncology market is projected to grow from $16.55 trillion in 2026 to $69.85 trillion by 2035, driven by immunotherapy advances and precision...
A major study of 160,691 adults reveals that financial, logistical, and emotional barriers,not lack of awareness,drive low cancer screening rates.
Cancer diagnoses in people under 50 are rising sharply across multiple types, prompting major health systems to lower screening ages.
Dense breast tissue affects nearly 50% of women and makes cancer harder to detect on standard mammograms, yet federal health systems don't cover advanced...
A major US study finds never-married adults have significantly higher cancer incidence across most cancer types, with risks peaking in those over 55.
A two-time breast cancer survivor discovered she carried a BRCA1 gene mutation through genetic testing, leading to early detection of stage 1 ovarian cancer.
Doctors can now identify cancer patients whose tumors will respond to immunotherapy drugs like dostarlimab using genetic testing, with 84 of 103 patients...
Immunotherapy is transforming melanoma treatment with checkpoint inhibitors like Keytruda, but a single dose can cost patients over $160,000, raising questions...
Researchers developed an AI tool that analyzes stomach cancer tissue slides to predict patient survival and treatment response with greater accuracy than...
A combination drug therapy doubled survival time for patients with metastatic uveal melanoma, a rare eye cancer with few treatment options.
A major investigation reveals how Merck's blockbuster cancer immunotherapy Keytruda generates massive profits while remaining unaffordable for patients...
Ovarian cancer often goes undiagnosed until advanced stages because early symptoms mimic common digestive issues.
ImmuneOncia's checkpoint inhibitor drug for rare NK/T-cell lymphoma just secured a major manufacturing partnership with Lonza, signaling confidence in the...
Prostate cancer cases are climbing in India, now accounting for 6.9% of all male cancers.
A major study shows MRI combined with mammograms detects breast cancer in BRCA carriers over 50 with 94% accuracy, nearly triple the mammogram-alone rate,...
Researchers are moving beyond one-size-fits-all cancer treatments by tailoring immunotherapy to each patient's unique tumor biology, with breakthrough...
Medicare covers colorectal and prostate cancer screenings at zero cost for eligible beneficiaries, but many seniors don't know about these life-saving...
A new 2026 study shows dense breasts alone don't automatically mean you need an MRI.
A breakthrough approach reprograms tumor cells to act as immune sentinels, triggering the body's own defenses.
Biological sex significantly affects cancer risk, with women facing higher rates of breast, ovarian, and cervical cancers, while men are more vulnerable to...
Colorectal cancer has become the leading cancer killer among adults under 50, with rates rising 2-3% yearly since the mid-1990s.
PARP inhibitors combined with hormone therapy are now a first-line standard for BRCA-mutated metastatic prostate cancer, offering stronger outcomes than...
New research shows cervical cancer rates among young women dropped 27% nationally since HPV vaccination began, but some states cut rates by over 50% while...